All the news Showing 4 of 204 articles from: Finance, funding & health economicsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources EASL publishes first comprehensive literature review on the burden of liver disease in Europe Eurekalert Inf Dis / 22 February 2013 Hepatitis C: A projection of the healthcare and economic burden in the UK RAND Corporation / 15 January 2013 Which patients should be prioritised for new hepatitis C treatments? Rob Camp / 23 November 2012 Younger patients with advanced liver disease caused by hepatitis C should be prioritised for treatment with newly licensed directly acting antivirals to achieve the biggest reductions in ill health and hospitalisation, according to ... Hepatitis C protease inhibitor therapy cost-effective in some circumstances Michael Carter / 21 February 2012 First-line hepatitis C therapy which includes a protease inhibitor can be cost-effective, investigators show in the Annals of Internal Medicine. The study showed that a triple combination of drugs, including the cheaper ... ← Prev1...1718192021Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Access to medicines & diagnostics Hepatitis C elimination Models of care Finance, funding & health economics National policy European policy International policy Activism and civil society Pharmaceutical industry Social issues Conference news Email bulletin archive